Forum Topic News
  • Conversation: Shire bags paediatric label expansion for Cinryze in the US

    • June 21, 2018 12:43 PM BST
    • Shire bags paediatric label expansion for Cinryze in the US

      US regulators have approved a label expansion for Shire’s Cinryze, allowing its use in children aged six and above with hereditary angioedema.
      HEA is a rare, debilitating and potentially life-threatening rare genetic disease that causes swelling in the face, extremities and GI tract, thought to affect around
      Cinryze (C1 inhibitor [human]), acquired by Shire through its purchase of ViroPharma in 2014, works by raising plasma levels of C1-INH in patients with the condition, who are prone to swelling due to an underlying deficiency of this protein.
      Read more: http://www.pharmatimes.com/news/shire_bags_paediatric_label_expansion_for_cinryze_in_the_us_1241152

Add Reputation

Do you want to add reputation for this member by this post?

or cancel